These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 21289031

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A.
    Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Teriparatide and denosumab combination therapy and skeletal metabolism.
    Idolazzi L, Rossini M, Viapiana O, Braga V, Fassio A, Benini C, Kunnathully V, Adami S, Gatti D.
    Osteoporos Int; 2016 Nov; 27(11):3301-3307. PubMed ID: 27250971
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E.
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [Abstract] [Full Text] [Related]

  • 9. Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
    Fahrleitner-Pammer A, Burr D, Dobnig H, Stepan JJ, Petto H, Li J, Krege JH, Pavo I.
    Bone; 2016 Aug; 89():16-24. PubMed ID: 27185100
    [Abstract] [Full Text] [Related]

  • 10. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [Abstract] [Full Text] [Related]

  • 11. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Koukoulis G, Avramidis A.
    Eur J Endocrinol; 2008 Mar; 158(3):411-5. PubMed ID: 18299476
    [Abstract] [Full Text] [Related]

  • 12. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalská D, Pavo I.
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [Abstract] [Full Text] [Related]

  • 13. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H.
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [Abstract] [Full Text] [Related]

  • 14. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 15. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 16. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 17. The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion.
    Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S, Gallagher JA, Vora JP, Fraser WD.
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3230-8. PubMed ID: 17550963
    [Abstract] [Full Text] [Related]

  • 18. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
    Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, Tsave O, Yovos JG, Yavropoulou MP.
    J Clin Endocrinol Metab; 2018 Mar 01; 103(3):1206-1213. PubMed ID: 29309589
    [Abstract] [Full Text] [Related]

  • 19. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.
    Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R.
    J Clin Endocrinol Metab; 2007 Sep 01; 92(9):3535-41. PubMed ID: 17609307
    [Abstract] [Full Text] [Related]

  • 20. Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis.
    Ebeling PR, Jones JD, Burritt MF, Duerson CR, Lane AW, Hassager C, Kumar R, Riggs BL.
    J Clin Endocrinol Metab; 1992 Oct 01; 75(4):1033-8. PubMed ID: 1400868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.